Nothing Special   »   [go: up one dir, main page]

HK1169455A1 - 阿爾茨海默病的診斷和治療 - Google Patents

阿爾茨海默病的診斷和治療

Info

Publication number
HK1169455A1
HK1169455A1 HK12110195.8A HK12110195A HK1169455A1 HK 1169455 A1 HK1169455 A1 HK 1169455A1 HK 12110195 A HK12110195 A HK 12110195A HK 1169455 A1 HK1169455 A1 HK 1169455A1
Authority
HK
Hong Kong
Prior art keywords
snp
snps
sample
gene
stage
Prior art date
Application number
HK12110195.8A
Other languages
German (de)
English (en)
French (fr)
Other versions
HK1169455B (zh
Inventor
Julie Williams
Michael John Owen
Original Assignee
University College Cardiff Consultants Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0911539A external-priority patent/GB0911539D0/en
Priority claimed from GB0913357A external-priority patent/GB0913357D0/en
Priority claimed from GB0917326A external-priority patent/GB0917326D0/en
Application filed by University College Cardiff Consultants Limited filed Critical University College Cardiff Consultants Limited
Publication of HK1169455A1 publication Critical patent/HK1169455A1/zh
Publication of HK1169455B publication Critical patent/HK1169455B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775Apolipopeptides
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HK12110195.8A 2009-07-03 2010-06-22 阿爾茨海默病的診斷和治療 HK1169455B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0911539.5 2009-07-03
GB0911539A GB0911539D0 (en) 2009-07-03 2009-07-03 Diagnosis of alzheimer's disease
GB0913357.0 2009-07-31
GB0913357A GB0913357D0 (en) 2009-07-31 2009-07-31 Diagnosis of alzheimer's disease
GB0917326A GB0917326D0 (en) 2009-10-03 2009-10-03 Diagnosis of alzheimer's disease
GB0917326.1 2009-10-03
PCT/GB2010/001208 WO2011001135A2 (en) 2009-07-03 2010-06-22 Diagnosis and treatment of alzheimer's disease

Publications (2)

Publication Number Publication Date
HK1169455A1 true HK1169455A1 (zh) 2013-01-25
HK1169455B HK1169455B (zh) 2017-07-07

Family

ID=

Also Published As

Publication number Publication date
CN102471800A (zh) 2012-05-23
CN103409511A (zh) 2013-11-27
US20120122703A1 (en) 2012-05-17
WO2011001135A2 (en) 2011-01-06
JP5917460B2 (ja) 2016-05-18
CA2766876C (en) 2020-01-28
EP2449134A2 (en) 2012-05-09
US20130288906A1 (en) 2013-10-31
AU2010267835A1 (en) 2011-12-15
NZ596614A (en) 2012-11-30
AU2010267835C1 (en) 2015-02-26
JP2014012007A (ja) 2014-01-23
CA2766876A1 (en) 2011-01-06
JP2012531195A (ja) 2012-12-10
WO2011001135A9 (en) 2011-02-24
AU2010267835B2 (en) 2014-11-06
WO2011001135A3 (en) 2011-06-30
JP5917395B2 (ja) 2016-05-11
EP2891723A1 (en) 2015-07-08
EP2891723B1 (en) 2017-10-04
US20150119264A1 (en) 2015-04-30
EP2449134B1 (en) 2016-07-27

Similar Documents

Publication Publication Date Title
EP2449134B1 (en) Diagnosis and treatment of alzheimer's disease
CA2275504C (en) Pharmacogenetic methods for use in the treatment of nervous system diseases
CN103930568A (zh) 用于治疗、诊断和监测阿尔茨海默病的方法
JP2007507460A (ja) 炎症性疾患の治療効力と関連している遺伝子多型の使用
US20150044239A1 (en) Compositions and Methods for Diagnosing, Preventing and Treating Intracranial Aneurysms
US9127316B2 (en) Markers associated with Alzheimer'S disease
AU2008242625A1 (en) Methods of diagnosing Alzheimer's disease and markers identified by set association
US20140171371A1 (en) Compositions And Methods For The Diagnosis of Schizophrenia
AU2014265063B2 (en) Diagnosis and treatment of Alzheimer's disease
US20120208718A1 (en) Schizophrenia treatment response biomarkers
HK1169455B (zh) 阿爾茨海默病的診斷和治療
EP2603606B1 (en) Methods and kits for of identifying a premature infant at risk of having or developing bronchopulmonary dysplasia
US20080194419A1 (en) Genetic Association of Polymorphisms in the Atf6-Alpha Gene with Insulin Resistance Phenotypes
WO2011031769A2 (en) Methods for risk assessment, treating, and diagnosing myocardial infarction
D'Aoust Examination of Candidate Exonic Variants that Confer Susceptibility to Alzheimer Disease in the Amish
Benitez et al. The PSEN1, p. E318G variant increases the risk of Alzheimer’s disease in APOE-ԑ4 carriers